Lisata Therapeutics Inc Fireside Chat Hosted by H.C. Wainwright & Co LLC (Virtual) Transcript
Okay. Good morning, everybody. My name is Joseph Pantginis, here at H.C. Wainwright. I'm the Director of Research and Managing Director of Equity Research as well. Very happy to provide this fireside chat with Lisata Therapeutics today. I've been covering the company for quite a long time even before when it was Caladrius. So it's been a very interesting ride and very happy to keep covering it. We do have a buy rating from a disclosure standpoint on Lisata.
And we're very happy to have with us David Mazzo, who is President and CEO; as well as Kristen Buck, who's the Executive Vice President of R&D and the Chief Medical Officer of the company. So thank you very much for being with us today, and I'd say let's just dive right in.
Questions & Answers
So David and Kristen, like I said, thanks for joining us
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |